Mayo Clinic Shows Myeloma Expertise Matters for Long Term Outcomes
The Mayo Clinic performed a study to see whether treatment at centers with significant myeloma expertise mattered to myeloma patients' long-term survival. In the recent publication in the Journal of Clinical Oncology, the investigators used the National Cancer Database to identify patients diagnosed with multiple myeloma between 2003 and 2011. The patients were divided into quartiles of myeloma patients treated per year.
- Q1 = facilities treating fewer than 3.6 patients per year
- Q2 = facilities treating 3.6-6.1 patients per year
- Q3 = facilities treating 6.1-10.3 patients per year
- Q4 = facilities treating over 10.3 patients per year
- Q1 = 5.2%
- Q2 = 12.6%
- Q3 = 21.9%
- Q4 = 60.3%
- Q1 = 26.9 months
- Q2 = 29.1 months
- Q3 = 31.9 months
- Q4 = 49.1 months
Patients who were treated for MM at higher-volume facilities had a lower risk of mortality compared with those who were treated at lower-volume facilities.Patients can successfully take advantage of both local care and myeloma expertise. Many patients will travel to consult with a myeloma expert who can give them treatment recommendations, strategy and craft a plan of attack. This plan can then be administered closer to home by a general oncologist. In this scenario, patients gain the expertise to extend their lives with the greatest convenience possible. You can find a myeloma specialist in our Myeloma Specialist Directory.